Picture the scene: the Sales teams from a CDMO and Sponsor are delighted to have finalized the principles of a manufacturing deal, the relationship is off to a strong start, but now the dreaded ‘template’ is issued. Suddenly, everything comes
OneSource Specialty Pharma Limited has received approval from the Saudi Food and Drug Authority (SFDA) for its generic Ozempic® (semaglutide) in Saudi Arabia, enabling commercialisation in partnership with Hikma Pharmaceuticals PLC across the Middle East and North Africa (MENA) region.
The FDA officially launched its Manufacturing PreCheck Pilot Program on February 1, 2026, introducing a two-phase regulatory framework designed to accelerate construction and approval of new U.S. pharmaceutical manufacturing facilities. The initiative arrives as the contract development and manufacturing organization
Shilpa Medicare Limited (SML) has entered into a binding agreement with NXI Therapeutics AG, a Swiss-based company, to develop and manufacture a New Chemical Entity (NCE) targeting autoimmune and alloimmune disorders. The collaboration marks a step in Shilpa’s expansion within
Ampersand Capital Partners has acquired Purna Pharmaceuticals, a provider of development and manufacturing services for liquid and semi-solid dosage forms serving pharmaceutical industry customers. The transaction marks the next phase of growth for Purna and expands Ampersand’s life sciences portfolio.
Altasciences has appointed Marie-Hélène Raigneau as Chief Executive Officer and named Chris Perkin to its Board of Directors, both effective February 24, 2026. The announcement follows a leadership transition that has been underway for the past 12 months. Perkin, who
WuXi Vaccines, a vaccine-focused CDMO and wholly owned subsidiary of WuXi Biologics, has received Good Manufacturing Practices (GMP) certification from Agência Nacional de Vigilância Sanitária (ANVISA) for its DP17 fill and finish facility in Suzhou. The certification follows comprehensive on-site
Syngene International has announced a strategic collaboration with Johns Hopkins University to advance early-stage drug discovery programmes and technology platforms emerging from the university’s research laboratories. The collaboration will focus on translating academic discoveries into therapeutic candidates. The partnership will
Rottendorf Pharma and Corealis Pharma have expanded their collaboration through a strategic partnership designed to streamline the end-to-end oral solid dosage (OSD) development journey. The transatlantic alliance combines Corealis’ early-stage OSD development and Phase I and II clinical supply expertise
FUJIFILM Biotechnologies has celebrated the grand opening of its expanded Teesside site, backed by an investment of approximately £400m from FUJIFILM Corporation, Japan. The expansion includes the largest single-use biopharmaceutical CDMO facility in the UK, according to the BDO bioTRAK
